Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2001

View Archived Issues

Epigenomics and MethylGene to collaborate on study of DNA methylation pattern changes

Xerion and Byk Gulden collaborate on target validation

Microbiotix and Phytobiotech to develop novel antibiotics

Biovail and GSK sign Wellbutrin and Zovirax licensing agreements

New compound discovered as a result of continued focus on topoisomerase inhibitors at Xenova

Canadian team designs bifunctional nitrosourea with signal transduction-inhibitory effects

Low-molecular-weight PAI-1 inhibitors show potential therapeutic efficacy for cancer

Lilly presents detailed update of late- and early-stage product pipeline

Novel antiangiogenic agent targeting alpha5beta1 integrin presented at AACR-NCI-EORTC meeting

Texas Biotechnology updates clinical trial progress

CEP-5214, a new VEGF receptor tyrosine kinase inhibitor, effective in prostate tumor models

Phase I/II trial of CpG-7909/Herceptin commences in treatment of breast cancer

Inhibition of histone deacetylase safely suppresses tumor growth in ovarian cancer-bearing mice

TolerRx to advance lead product with completion of financing

OvaRex associated with improvement in clinical outcome and good safety in advanced ovarian cancer

Abbott's new H3 receptor antagonists described in recent patent

Diagnostic and therapeutic radiolabeled epothilone derivatives

Nucleosides useful as antiviral and anticancer agents disclosed by SRI

Significant antitumor activity and excellent safety demonstrated for ACRL-B4

AC-90179, a new 5-HT2A inverse agonist from Acadia

New chemokine IL-8 receptor antagonists under study at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...